Figure - available via license: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Content may be subject to copyright.
Source publication
In recent years, treatment of acute lymphoblastic leukemia (ALL) has improved substantially, leading to longer survival. This has necessitated a greater focus on health-related quality of life (HRQoL), but data are lacking. In a part-prospective, part-retrospective study, we enrolled 219 adults with ALL in France to assess the impact of key disease...
Contexts in source publication
Context 1
... for the FACT-Leu total score, FACT-G and leukemia subscale scores (Table 3) and the EQ-5D-3L (Supplementary Table 1) were consistent with those of the QLQ-C30 (Table 3). ...Citations
... Due to the complicated nature of the disease, clinical assessments for risk assignment, and effects of therapies, ALL/LBL has an important impact on the quality of life of patients and caregivers and there are also emotional, financial, and developmental effects. 7,8 Prognosis is generally poor in adults (5-year survival of 40% to 70%), with older age associated with worse survival, 9 while children and adolescents have better projections, including remission in 98% of patients, a 5-year survival greater than 90%, and long-term eventfree survival of 85%� 10 ...
... The pivotal study can only highlight that crisantaspase recombinant is associated with measurable asparaginase activity (an NSAA above a threshold of 0�1 IU/mL, which was previously set as an important limit of clinical importance)� 8,15,16 This end point, however, is used and should be interpreted as a surrogate for important clinical outcomes� ...
... The clinical features of ALL/LBL include findings associated with bone marrow infiltration, such as anemia, neutropenia, and/or thrombocytopenia� 9 Patients are affected by different clinical signs and symptoms, such as fatigue, infections, bleeding, bone pain, arthralgia, hepatomegaly, splenomegaly, and lymphadenopathy� Due to the complicated nature of the disease, clinical assessments for risk assignment, and the effect of therapies, ALL/LBL has an important impact on the quality of life of patients and caregivers and also has emotional, financial, and developmental impacts. 7,8 The diagnosis requires clinical and laboratory tests (e�g�, complete blood count, blood chemistry) and an oncologic evaluation with bone marrow aspirate and biopsy, lumbar puncture, flow cytometry, and cytogenetic testing, among others, to detect genetic alterations and factors of prognostic value� Prognosis is generally poor in adults (5-year survival is 40% to 70%), with older age associated with worse survival, 9 whereas children and adolescents have better projections, with 98% achieving remission, a 5-year survival above 90%, and long-term event-free survival of 85%� 10 The overall prognosis is likely correlated with an increase in adverse cytogenetic and molecular risk factors in older age groups� Cytogenetics and the presence of minimal residual disease after induction and/or consolidation therapies are the most important factors for determining the prognosis� 6 ...
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses crisantaspase recombinant (Rylaze), solution for intramuscular injection, 10 mg/0.5 mL (20 mg/mL). Indication: Indicated as a component of a multidrug chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 year or older who have developed hypersensitivity to Escherichia coli–derived asparaginase.
